Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA radioligand therapy in advanced salivary gland cancer
NL-OMON48525Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium (177Lu) PSMA in salivary gland cancer (SGC), adenoid cystic carcinoma (ACC) and salivary duct carcinoma (SDC), sponsored by Radboud University Medical Center. Primary endpoint: Safety. Started Jul 2020; status: completed.
02
Drugs
lutetium (177Lu) PSMA
03
Conditions
salivary gland cancer (SGC)adenoid cystic carcinoma (ACC)salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on NL-OMON48525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48525.